Clinical Trial Update: Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

View source ↗

Summary

An update on Boehringer Ingelheim's expanded access program for nintedanib in idiopathic pulmonary fibrosis, noting that the program is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)
• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Status: NO_LONGER_AVAILABLE